drugset / Trial / NCT05829187

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

NCT05829187

RandomizedParallel-groupSingle-blindTreatment

Summary

Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported. A study is conducted to assess the efficacy and safety extract of bitter melon (Momordica charantia/MC) regimens compared to the combination of dihydroartemisinin piperaquine primaquine (DHP+PQ) on the sexual and asexual stage of P. Falciparum uncomplicated in Sumba Barat Daya District, Indonesia

Timeline

Start
2022-11-01
Primary completion
2022-12-31
Completion
2022-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 2 mg/kg
Subject ARTENIMOL Small molecule 4 mg/kg
Subject Primaquine Small molecule 0.25 mg/kg
Subject bitter melon Unknown 325 mg
Subject bitter melon Unknown 650 mg
Subject piperaquine Small molecule 16 mg/kg
Subject piperaquine Small molecule 32 mg/kg